You can find our latest news below
Japanese Association of Clinical Laboratory Systems (JACLaS) is again around the corner. This year, we are thrilled to announce that our dynamic sales duo, Teppo Heimo and Outi Vilamo, will once again be representing our company at the JACLaS 2025, from 3th to 5th of October.
We are pleased to announce the launch of three new HIV-1 antigen products—8H12, 8H13, and 8H16—that expand our portfolio of solutions for HIV diagnostics.
With the autumn breeze, flu season in the Northern Hemisphere is about to begin. While influenza viruses circulate year-round, flu activity typically peaks between December and February.
We are proud to announce the addition of a new cardiac marker product — recombinant Growth Differentiation Factor 15 (GDF15) antigen (Cat. #8DF5).
While many people now believe that COVID-19 is milder and no longer a threat, it can still pose serious risks. The disease is particularly dangerous for individuals who are immunosuppressed, have chronic medical conditions, or are older.
With new variants continuing to emerge, the virus remains unpredictable. This rapid evolution underscores the importance of tools that can reliably detect not only older strains but also newly emerging ones.
Hytest is excited to announce new Cat. # 4IGF4 IBP3m Monoclonal Anti-Insulin-Like Growth Factor Binding Protein 4.
Hytest is thrilled to announce the launch of new high-affinity monoclonal antibodies (MAbs) (Cat. # 2TS11cc — MAbs TS13, TS18, TS21, TS25, TS31, and TS32) specific to human TSH.
Anti-human alpha-fetoprotein (AFP) is a single-chain glycoprotein. It is one of the major proteins in fetal circulation. In adults, AFP concentrations are elevated during pregnancy and in certain malignant diseases. Clinically, AFP levels reflect tumor size and correlate with disease progression, making them a valuable indicator for monitoring treatment response and prognosis.
Hepatitis C is an inflammation of the liver caused by hepatitis C virus (HCV). The virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness to a serious lifelong illness including liver cirrhosis and cancer.
Beta-CrossLaps (β-CTX), also known as beta C-terminal telopeptides, have been designated as reference bone turnover markers (BTMs), together with Procollagen Type I N-terminal propeptide (PINP), in blood by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).
Hytest is excited to introduce a new set of monoclonal anti-Procollagen
Type I N-Propeptide (P1NP) antibodies.
Hytest is excited to announce the launch of a new antibody: Recombinant Anti-Human Carcinoembryonic Antigen (CEA) (Cat. # 4CA30cc, MAb: RE16).
We are proud to announce that Selma Salonen has been selected as the winner of the fifth EFLM-Hytest Cardiac Marker Award. The award was presented by the EFLM President during the Opening Ceremony of the IFCC-EFLM European Congress – EuroMedLab, held in Brussels in May 2025.
Hytest is proud to announce the global launch of its latest innovation: recombinant human Thyroid-Stimulating Hormone (TSH), available under Cat. # 8HTS7.
The article, titled “Design and Analytical Evaluation of Novel Cardiac Troponin Assays Targeting Multiple Forms of the Cardiac Troponin I–Cardiac Troponin T–Troponin C Complex and Fragmentation Forms,” presents a comprehensive analytical evaluation of novel cardiac troponin assays designed by Hytest scientists in collaboration with Dr. Zhenlu Zhang (Wuhan Asia Heart Hospital), Dr. Fred Apple (Hennepin Healthcare/Hennepin County Medical Center), and Dr. Yi Zhang (Mindray Bio-Medical Electronics Co.).
Hytest looks forward to participating in ADLM 2025 (formerly AACC), taking place July 29–31 in Chicago, USA. Come visit us at Booth #1724 to connect with our team and learn how our antibodies and antigens can support your diagnostic solutions.
We are proud to share that Professor Peter Kavsak has been selected as the recipient of the 2025 IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics, sponsored by Hytest.
Hytest is excited to announce the launch of its new HIV p24 monoclonal antibodies (MAbs) under Cat. # 3H24. All 7 MAbs--GA12, GA17, GA32, GA34, GA38, GA39, and GA54-- are designed to be used for the development of next-generation HIV p24 antigen immunoassays.
Hytest is excited to announce the launch of its recombinant HCV NS3 antigen (Cat. # 8HC53)—a high-purity reagent developed as capture or detection material for in vitro immunoassays aimed at the qualitative detection of antibodies to Hepatitis C Virus (HCV).
Since 1994, Hytest has systematically studied the biochemical and immunochemical properties of cardiac troponins and has developed comprehensive antibody selection strategies for cTnI and cTnT assay development, backed by a strong scientific foundation. In 2004, Hytest’s cardiac troponin complex was chosen as a raw material for the international troponin standard. Through all these years, we have been providing highly specific and sensitive antibodies and antigens for the development of your immunological assays.
Copyright © 2025 Hytest Ltd.